SUMMARY The hemodynamic effects of intravenous verapamil administration were examined in 27 patients with hypertrophic cardiomyopathy. Increasing doses of verapamil produced small increases in heart rate and cardiac output and a significant decrease in systolic blood pressure, but had no significant effect on mean pulmonary artery wedge pressure or left ventricular end-diastolic pressure. The highest dose of verapamil increased heart rate from 72 ± 3 to 81 ± 6 beats/min and reduced systolic blood pressure from 118 ± 8 to 99 ± 5 mm Hg (p < 0.005 Because increases in myocardial cell calcium content increase myocardial contractility,9 we were intrigued by the studies of the hereditary cardiomyopathy of Syrian hamsters.' 1-2 These studies showed that myocardial calcium uptake and content are increased and that the metabolic and anatomic abnormalities can be prevented by the administration of verapamil, an agent that blocks inward calcium transport across cell membranes.
FOR MANY YEARS propranolol has been the primary pharmacologic therapeutic agent for symptomatic patients with hypertrophic cardiomyopathy.'-3 The salutary hemodynamic and symptomatic effects produced by propranolol derive from its inhibition of sympathetic stimulation to the heart.4 5 However, there is no evidence that the drug alters the primary cardiomyopathic process; many patients remain in or return to their severely symptomatic states, and some die, despite its administration. 2, 3 If propranolol therapy fails to control symptoms in patients with obstruction to left ventricular outflow, an operation such as septal myotomy-myectomy must be considered. Although this operation provides marked symptomatic benefit to most patients with obstruction to left ventricular outflow, the operative From the Cardiology Branch, National Heart, Lung, and Blood risks are 5-10O%.' 7 Moreover, operation is not a viable option for patients without obstruction. Therefore, new approaches to the nonoperative treatment of this disease are clearly necessary.
One of the striking characteristics of the left ventricle in hypertrophic cardiomyopathy is its hypercontractile state, manifest by end-systolic apical cavity obliteration and increased ejection fraction. One hypothesis for this hypercontractility suggests that there are increased amounts of norepinephrine in the left ventricle of patients with hypertrophic cardiomyopathy.8 However, this hypothesis has never been confirmed and there is no explanation for the hypercontractile state in this disorder.
Because increases in myocardial cell calcium content increase myocardial contractility,9 we were intrigued by the studies of the hereditary cardiomyopathy of Syrian hamsters.' [1] [2] All patients were in normal sinus rhythm when hemodynamic measurements were made. Measurements were initially recorded in the control state and then 10-20 minutes after each dose of verapamil. In all patients who had basal left ventricular outflow tract gradients <70 mm Hg and in an occasional patient with a gradient of 70-90 mm Hg, the Valsalva maneuver, amyl nitrite inhalation and intravenous isoproterenol infusion were performed after basal measurements were obtained. When possible, left ventricular outflow gradients obtained before and during verapamil infusion were compared at similar heart rates (± 10 beats/min) and systolic blood pressures (± 15 mm Hg). Although verapamil administration sometimes lowered systemic systolic blood pressure by more than 15 mm Hg (vs control pressure), systolic pressure was never more than 15 mm Hg above that of the control state.
Verapamil Infusions
Verapamil was infused into a peripheral vein in three dosages: 0.007, 0.014 and 0.021 mg/kg/min. Each infusion was preceded by a 0.1-mg/kg bolus of verapamil administered over 2 minutes. In the first 10 patients studied, only 0.007 mg/kg/min was used and hemodynamic measurements were made at 10 and 20 minutes. When multiple dosages were administered, measurements were made after 10 minutes of infusion, whereupon the next increment in drug dosage was begun, preceded by a repeat bolus administration.
Statistics
Data were analyzed statistically using the two-tailed t test for paired data.
Results
Basal Hemodynamics
The two higher verapamil dosages produced a small increase in heart rate, while systolic blood pressure decreased significantly at all three dosage levels (table 1, figs. 1 and 2). Mean pulmonary artery wedge pressure for the overall group did not change significantly with increasing verapamil dosages (table  1 and fig. 3 ). However, in five of seven patients, a high control wedge pressure fell by 4-12 mm Hg. Only four of 19 patients with normal control wedge pressure developed an abnormal mean pulmonary artery wedge pressure (> 15 mm Hg) during verapamil infusion ( fig.  3 ). Left ventricular end-diastolic pressure for the group did not change significantly (table 1 and fig. 4 ). However, left ventricular end-diastolic pressure fell (10 patients) or was unchanged (two patients) in 12 of the 15 patients who had abnormal pressures in the fig. 7 ). Both patients in whom verapamil had no effect on the gradient induced by amyl nitrite had a systolic blood pressure >30 mm Hg lower than in the control state at the time of the peak gradient measurement ( fig. 7) . One of these patients received only the lowest dose of verapamil. All from the portal blood before reaching the systemic circulation, there will probably be great individual variation in the hemodynamic effect of a given dosage. Thus, our results should not be construed as indicating that verapamil, when administered as a therapeutic agent, can usually be expected to be effective and totally safe. Patients receiving this medication must still be watched closely for signs of congestive heart failure as well as a depression of either the sinus node or conduction in the atrioventricular tissue. In addition, blood pressure must be frequently monitored in both the supine and upright positions to insure that there is no tendency for an excessive decrease in peripheral vascular resistance.
The basic pharmacologic mechanisms by which verapamil exerts its diverse effects are presently unclear. Although earlier studies suggested verapamil had f-adrenergic receptor blocking activity,19 subsequent investigations have refuted this concept.20 More recently, verapamil has been shown to inhibit transmembrane fluxes of calcium.2' It appears that the drug specifically interferes with calcium transport occurring through the so-called slow channel. 22 Although there is some evidence that verapamil blocks other ion fluxes through the slow channel,23 it is unclear whether such ionic transport actually occurs normally, or, if it does, what effect verapamil has on this transport.
Regardless of its precise biochemical effects, verapamil's major cardiovascular actions are to diminish the rate of conduction through atrioventricular tissue24 and to relax vascular smooth muscle25, 26 as well as other smooth muscle throughout the body.27 Potential adverse effects of the drug accrue from its ability to depress sinus node function,28 to produce atrioventricular block28 and to cause severe hypotension secondary to its vasodilatory activity. The drug has been shown to be capable of decreasing myocardial contractility in vitro at high concentration. 29 Although depression in contractility also occurs experimentally in vivo,28' 30 other studies have not confirmed this finding.3' -3 These conflicting results may result from the different drug doses used, the different experimental models and the relative contributions of the direct and indirect actions of verapamil in the various studies.
The mechanisms responsible for the beneficial hemodynamic effects of verapamil in patients with hypertrophic cardiomyopathy probably derive, as do its adverse effects, from inhibition of calcium movement into the myocardial cell. Any agent that produces a decrease in the contractile state of the heart should, nonspecifically, diminish the degree of left ventricular outflow obstruction in patients with hypertrophic cardiomyopathy.4 This is believed to be the major mechanism by which propranolol reduces the outflow gradient in such patients. Thus, if verapamil decreases the myocardial contractile state by decreasing normal calcium transport or by correcting a basic abnormality involving excessive uptake of calcium by the myocardium, a decrease in outflow obstruction would be anticipated. Further studies will be necessary to determine which, if either, mechanism applies to patients with hypertrophic cardiomyopathy.
Regardless of whether the beneficial hemodynamic effects exerted by verapamil are due to a nonspecific effect of the drug on myocardial contractile state or to reversal of the biochemical consequences of a basic metabolic abnormality, our results suggest that verapamil may provide a new alternative to propranolol and operation in the treatment of hypertrophic cardiomyopathy. Moreover, if results of further studies suggest a specific role of calcium antagonists in the treatment of hypertrophic cardiomyopathy, a much broader application of verapamil to the therapy of this disease may be indicated.
